| Filing Date |
Description |
| 2012-11-08 |
The information in this Form 8-K
(including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, ... |
| 2012-11-08 |
The information in this Form 8-K
(including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, ... |
| 2012-08-31 |
On August 30, 2012, the Company entered into a
subscription agreement (the “Subscription Agreement”) with funds managed by QVT Financial LP relating to the issue and sale of an aggregate of 6,367,853 shares of the Company’s common stoc ... |
| 2012-08-08 |
On August 8, 2012, Achillion Pharmaceuticals, Inc. (the “Company”) announced its financial results for the fiscal quarter ended
June 30, 2012. The full text of the press release issued in connection with the announcement is furnished as Exh ... |
| 2012-08-08 |
On August 8, 2012, Achillion Pharmaceuticals, Inc. (the “Company”) announced its financial results for the fiscal quarter ended
June 30, 2012. The full text of the press release issued in connection with the announcement is furnished as Exh ... |
| 2012-06-28 |
Effective June 25, 2012, Achillion Pharmaceuticals, Inc. (the
“Company”), entered into a letter agreement (the “Agreement”) with Dr. Elizabeth A. Olek, the former Senior Vice President and Chief Medical Officer of the Company, in ... |
| 2012-06-11 |
On June 10, 2012, Nicholas Simon, a Class I director and a member of the Compensation Committee of the Board of Directors, resigned
from the Board of Directors of Achillion Pharmaceuticals, Inc. (the “Company”). ... |
| 2012-06-06 |
On June 3, 2012, Dr. Elizabeth A. Olek, the Senior
Vice President and Chief Medical Officer of Achillion Pharmaceuticals, Inc. (the “Company”), provided notice of her intention to resign from the Company, effective June 18, 2012. ... |
| 2012-03-08 |
The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, ... |
| 2012-01-17 |
On January 11, 2012, the Compensation Committee of the Board of Directors
(the “Compensation Committee”) of Achillion Pharmaceuticals, Inc. (the “Company”) authorized the payment of the remaining approximately one-half of the annu ... |
